uniQure NV
UQ1
Company Profile
Business description
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Contact
Paasheuvelweg 25
AmsterdamNH1105 BP
NLDT: +31 202406000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
209
Stocks News & Analysis
stocks
Are declining Chinese births a red flag for A2 Milk?
Demographic challenges in A2’s largest market lead to sell-off.
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,109.10 | 16.70 | 0.18% |
| CAC 40 | 8,062.58 | 49.44 | -0.61% |
| DAX 40 | 24,703.12 | 255.94 | -1.03% |
| Dow JONES (US) | 48,488.59 | 870.74 | -1.76% |
| FTSE 100 | 10,126.78 | 68.57 | -0.67% |
| HKSE | 26,445.47 | 42.04 | -0.16% |
| NASDAQ | 22,954.32 | 561.07 | -2.39% |
| Nikkei 225 | 52,806.70 | 184.40 | -0.35% |
| NZX 50 Index | 13,418.76 | 155.17 | -1.14% |
| S&P 500 | 6,796.86 | 143.15 | -2.06% |
| S&P/ASX 200 | 8,788.60 | 19.70 | 0.22% |
| SSE Composite Index | 4,116.65 | 3.00 | 0.07% |